NCT06507059Active, not recruitingPhase 3
Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
A Phase 3 Study Comparing Clinical Outcomes in People Living With HIV (PLHIV) With Suboptimal Adherence Treated With Injectable Long-acting Antiretrovirals Versus Oral Antiretrovirals
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This study aims to determine whether people living with HIV (PLHIV) with suboptimal medical adherence can achieve better viral suppression with long-acting antiretrovirals (LA) compared to all-oral antiretrovirals.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 7 Jul 2024
- Start date
- 19 Jul 2024
- Primary completion date
- 6 Aug 2025
- Lead sponsor
- Chang Gung Memorial Hospital
- Diseases
- HIV
- NCT number
- NCT06507059
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 40
- From 19 Jul 2024 to the primary completion date, 6 Aug 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For those currently undergoing oral antiretroviral therapy, who have started or restarted oral ART for less than six consecutive months before screening.
- Previously undergone HIV drug resistance testing and known to have resistance mutations to either cabotegravir or rilpivirine.
Other illness
- Individuals who cannot receive treatment for hepatitis B during the period of transitioning to long-acting injections, if they are hepatitis B carriers.
Other
- Unable to commit to maintaining contact with the research team throughout the study.
- Individuals with buttock fillers.
- Women who are planning to become pregnant, pregnant, or currently breastfeeding.
Who the study is looking for
- Willing to sign the written informed consent form for male and female participants aged 18 and above.
- At the time of enrollment, diagnosed with HIV infection for a minimum of 12 months.
- Under oral antiretroviral treatment (ART), which can be irregular or interrupted, with the most recent viral load ≥ 200 copies/mL.
- Body weight ≥ 35Kg.
- Willing to maintain contact with the research team throughout the study (provide accurate and reachable phone numbers, social accounts like Line, or reliable contact information of family or friends).
- Willing to receive gluteal (buttocks) drug injections.
- Willing to transition back to oral medication or follow the recommended treatment prescription according to the then-current national treatment guidelines after discontinuation of long-acting injectable drugs.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chang Gung Memorial Hospital, Keelung Coordinator of this site? Confirm its status | Keelung | Taiwan | Unknown status |
| Chang Gung Memorial Hospital-Taipei Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
| Taoyuan General Hospital, Ministry of Health and Welfare Coordinator of this site? Confirm its status | Taoyuan | Taiwan | Unknown status |
| Chang Gung Memorial Hospital, Linkou Coordinator of this site? Confirm its status | Taoyuan | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.